Induced Pluripotent Stem Cells
GMP iPSC reprogramming, gene editing and differentiation
Leading Industry Experts
OmniaBio has generated and characterized over 200 induced pluripotent stem cell (iPSC) lines. This deep expertise ensures we can meet the unique requirements of each client. Our team of iPSC industry leaders take a personalized approach to each project and can help you at every step.
iPSC CDMO Offerings
- Good Manufacturing Practices (GMP)-compliant reprogramming platforms to produce therapeutic-grade iPSC lines
- Expertise using a variety of different nucleases and delivery methods, including CRISPR-Cas9, to generate gene-edited iPSC lines with knock-in, knock-out, and single nucleotide polymorphism (SNP) modifications
- An optimized screening approach for fast and accurate identification of single-cell clones of interest
- Process scale-up for the generation of a variety of differentiated cell types
- An in-house analytics platform to enable cell line characterization
Services for Your Project Phase
Process
Development
Experts in optimization to ensure reliable scale-up to produce cell and gene therapies.
GMP
Manufacturing
Our state-of-the-art facility is equipped with the tools and flexibility to manufacture your product at commercial scale.
Analytical
Development
Providing a robust suite of analytical capabilities that are integrated through your product’s lifecycle to support the development process.
Regulatory
Support
With in-depth knowledge, we can guide you through the regulatory landscape to approval.
Our Expertise on Demand
Related Thought Leadership & Resources
November 20, 2024 (Toronto, Ontario) – LineaBio, a cell line company, today announced it has submitted a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for its flagship unmodified, off-the-shelf,...
The site will add state-of-the-art CGT capacity and employ artificial intelligence and automation to achieve critical product supply efficiencies for North American and global biotherapy clients.Hamilton, ON., October 17, 2024 – Today OmniaBio Inc. will announce...
CDMO collaboration propels cell replacement therapy targeting Duchenne muscular dystrophy forward, with consequences for the role of AI in cell therapy. September 9, 2024 (BOSTON, MA and HAMILTON, Ontario) – Somite Therapeutics, a tech-bio company harnessing big...